Lefu Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lefu Huang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chuanying Geng
Department of Haematology Beijing Chaoyang Hospital, Capital Medical University Beijing China
1 shared publication - Gailing Zhang
Hebei Yanda Lu Daopei Hospital, Langfang 065201, China
1 shared publication Guoliang Qiao
Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, CA, China (mainland)
1 shared publication- Hong-Hu Zhu
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
1 shared publication - Hui Wang
Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China.
1 shared publication - Jianqiang Li
Hebei Senlang Biotechnology Co., Ltd., Shijiazhuang 050000, China
1 shared publication
Latest Publications
- 16 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2341-2345
Deep molecular remission and encouraging survival without transplantation: V‐ CAG for arsenic‐resistant relapsed APL
- 16 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2341-2345
Deep molecular remission and encouraging survival without transplantation: V‐ CAG for arsenic‐resistant relapsed APL
- Open Access
Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
CD19 chimeric antigen receptor T-cell (CAR-T) therapy is efficacious for refractory/relapsed (R/R) B-cell hematological malignancies, yet relapse due to CD19 antigen escape remains a challenge. Our trial explored simultaneous targeting of multiple B-cell antigens as a therapeutic approach that may reduce the risk of relapse. We tested the safety and efficacy of CAR19/22 T-cell cocktail therapy including murinized and humanized products among patients with R/R aggressive B-cell lymphoma. In the group that received the humanized product, 11/12 (91.7%) patients achieved an objective response, including 9/12 (75%) complete responses (CRs) by day 28. The overall response rate and CR rate in the murinized group was 92.9% (13/14) and 42.9% (6/14), respectively. Nine of 12 (75%) patients in the humanized group maintained CR at month 3 following infusion, compared to 5/14 patients (35.7%) in the murinized group. Progression-free survival (PFS) was more favorable in the humanized compared to the murinized group. Most patients had mild cytokine release syndrome (CRS) (grade 1–2) in both groups. This study demonstrates that CAR19/22 T-cell cocktail therapy is safe and effective for R/R B-cell lymphoma and that patients treated with a humanized CAR-T exhibited better efficacy compared to patients treated with a murinized CAR-T therapy.
Open AccessSafety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
CD19 chimeric antigen receptor T-cell (CAR-T) therapy is efficacious for refractory/relapsed (R/R) B-cell hematological malignancies, yet relapse due to CD19 antigen escape remains a challenge. Our trial explored simultaneous targeting of multiple B-cell antigens as a therapeutic approach that may reduce the risk of relapse. We tested the safety and efficacy of CAR19/22 T-cell cocktail therapy including murinized and humanized products among patients with R/R aggressive B-cell lymphoma. In the group that received the humanized product, 11/12 (91.7%) patients achieved an objective response, including 9/12 (75%) complete responses (CRs) by day 28. The overall response rate and CR rate in the murinized group was 92.9% (13/14) and 42.9% (6/14), respectively. Nine of 12 (75%) patients in the humanized group maintained CR at month 3 following infusion, compared to 5/14 patients (35.7%) in the murinized group. Progression-free survival (PFS) was more favorable in the humanized compared to the murinized group. Most patients had mild cytokine release syndrome (CRS) (grade 1–2) in both groups. This study demonstrates that CAR19/22 T-cell cocktail therapy is safe and effective for R/R B-cell lymphoma and that patients treated with a humanized CAR-T exhibited better efficacy compared to patients treated with a murinized CAR-T therapy.
- Retraction
- 13 June 2019
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 25, 4400
Retracted: Expression of Lymphocyte-Activation Gene 3 (LAG-3) Immune Checkpoint Receptor Identifies a Tumor-Reactive T Cell Population in the Peripheral Blood of Patients with Colorectal Cancer
This article is retracted due to authors’ claims in regards to errors in data and statistical analyses. Authors’ message: We greatly regret to inform you that we just discovered some fatal errors in the statistical analysis, in which we ...
- 13 June 2019
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 25, 4400
RetractionRetracted: Expression of Lymphocyte-Activation Gene 3 (LAG-3) Immune Checkpoint Receptor Identifies a Tumor-Reactive T Cell Population in the Peripheral Blood of Patients with Colorectal Cancer
This article is retracted due to authors’ claims in regards to errors in data and statistical analyses. Authors’ message: We greatly regret to inform you that we just discovered some fatal errors in the statistical analysis, in which we ...